doctors Katalin Kariko and Drew Weissman - nobel prize winners

WORLD-CHANGING MRNA VACCINES
from Penn Medicine

Penn Medicine is home to the breakthrough messenger ribonucleic acid (mRNA) technology that enabled the highly successful COVID-19 vaccines from Moderna and Pfizer-BioNTech. Now the path is set for a whole new class of mRNA vaccines with the potential to eradicate countless other diseases, even cancer.

How Do mRNA Vaccines Work?

Many vaccines use a weakened or dead version of the actual virus to stimulate an immune response against disease. Development of these vaccines can be lengthy and costly. Modifying them quickly if needed is difficult.

In contrast, mRNA vaccines use a genetic code to tell the body's cells to produce proteins that train the immune system. The result: “plug-and-play” vaccines with rapid development times and lower costs.

What's Next? The Future of mRNA Vaccines for “Every Imaginable Infectious Disease”

The mRNA platform created at Penn Medicine ignited a global renaissance in RNA biology research. Scientists in industry and at universities worldwide are finding new and innovative ways to use mRNA technology to prevent and treat disease.

“We're working on every imaginable infectious disease."

Drew Weissman, MD, PhD, Roberts Family Professor in Vaccine Research

At Penn, our researchers are using the mRNA platform to create vaccines for a wide variety of conditions.

mRNA Vaccines for Infectious Diseases

Before COVID-19 erupted, a Penn-developed mRNA influenza (flu) vaccine was already in clinical trials. This existing work directly contributed to the speed at which drug makers could produce the mRNA COVID-19 vaccines.

With fast development and production times, mRNA vaccines are ideal for protection against new infectious diseases and variants of existing ones. Our researchers are at the forefront of mRNA vaccines for numerous infectious disease vaccines, including the following.


mRNA Vaccines for Cancer

While the mRNA vaccines for COVID-19 and other infectious diseases prevent disease, mRNA technology can also help treat existing diseases like cancer. The platform's flexibility allows researchers to create mRNA cancer vaccines that activate the immune system to attack cancer cells.


mRNA Treatment for Food and Environmental Allergies

Penn researchers are working on a vaccine to stop the body's production of immunoglobulin E (IgE) antibodies that can cause severe attacks in people with peanut allergies. Additional efforts target dust mite allergies.


mRNA and Genetic Diseases

Penn scientists are studying ways that mRNA could deliver replacement genes or repair defective genes to treat diseases such as:


mRNA for Heart Attack and Stroke

Excess cholesterol is a leading risk factor for heart attack and stroke. Penn researchers are using mRNA technology to modify liver genes, thereby permanently reducing cholesterol levels and protecting against heart attack and stroke.

“We expect that the [vaccine's] effect will be permanent with lifelong protection against heart disease.”

Kiran Musunuru, MD, PhD, MPH, ML, director of the Genetic and Epigenetic Origins of Disease Program at Penn Cardiovascular Institute

mRNA for Heart Failure

Heart failure happens when the heart muscle weakens or stiffens, and it can no longer pump enough blood to meet the body's needs. Fibrosis, a result of heart injury and inflammation, is one condition that causes heart muscle to stiffen.

Penn scientists developed a technique in which mRNAmolecules instruct T cells to blast the fibrous tissue and restore heart function. This technology holds also promise to treat fibrosis in the kidneys, lungs, liver and joints.

Read more:


mRNA Therapies for Neurodevelopmental Disorders

Penn scientists are considering RNA therapeutics for reducing conditions leading to fatal neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

"We now have the chance to build therapies for previously untreatable diseases."

Jonathan Epstein, MD, Senior Vice President and Chief Scientific Officer

Expanding Global Access to mRNA Vaccines

When countries can affordably and sustainably manufacture their own vaccines, global health is a greater possibility. We collaborate with world governments to establish Good Manufacturing Practices (GMP) sites and train local scientists to develop mRNA vaccines for local diseases.

Meet the Nobel Prize Laureates Behind mRNA Science

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, invented the messenger mRNA technology that serves as the foundation of the Pfizer-BioNTech and Moderna vaccines. The scientists received the world's most prestigious awards for their discovery science efforts, including the Nobel Prize in Medicine, Lasker-DeBakey Clinical Medical Research Award, the Breakthrough Prize and the Albany Medical Center Prize in Medicine and Biomedical Research.

Penn Institute for RNA Innovation

The Penn Institute for RNA Innovation brings together myriad scientists and vast expertise to accelerate breakthrough discoveries and develop the next generation of RNA therapies. Currently under construction, the institute is designed to harness the power of worldwide, interdisciplinary collaborations.